Patents by Inventor Linda HIBBERT

Linda HIBBERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS
    Publication number: 20230322895
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: October 12, 2023
    Inventors: Conor HAYES, Linda HIBBERT, Nathaniel Ross LIDDY, Tara MAHON, Marine RAMAN
  • T cell receptors
    Patent number: 11505590
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 22, 2022
    Assignee: IMMUNOCORE LIMITED
    Inventors: Conor Hayes, Linda Hibbert, Nathaniel Ross Liddy, Tara Mahon, Marine Raman
  • T CELL RECEPTORS
    Publication number: 20190092834
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: April 7, 2017
    Publication date: March 28, 2019
    Inventors: Conor HAYES, Linda HIBBERT, Nathaniel Ross LIDDY, Tara MAHON, Marine RAMAN